<DOC>
	<DOCNO>NCT01226797</DOCNO>
	<brief_summary>This study evaluate effect PF-04136309 patient chronic hepatitic C virus infection abnormal liver enzyme .</brief_summary>
	<brief_title>Safety And Efficacy Of Oral PF-4136309 In Patients With Chronic Hepatitis C Infection And Abnormal Liver Enzymes</brief_title>
	<detailed_description>Study recruitment stop Dec 15 , 2011 due difficulty enrol targeted number patient . Subjects currently enrol study complete study per protocol . There safety concern involve decision stop enrollment . The new anticipate Last Subject Last Visit ( LSLV ) February 2012 .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Chronic HCV infection ALT &gt; 1.5 &lt; 10 time upper limit normal Decompensated severe liver disease define one follow criterion : Prior liver biopsy show cirrhosis . International Normalized Ratio ( INR ) great equal 1.5 . Total bilirubin great equal 1.5X ULN , &gt; 2X ULN unconjugated bilirubin . Serum albumin normal . ALT aspartate aminotransferase ( AST ) &gt; 10 x ULN . Evidence portal hypertension include splenomegaly , ascites , encephalopathy , and/or esophageal varix . Presence human immunodeficiency virus ( HIV ) . Coinfection hepatitis B virus ( HBV ) . Coinfection Epstein Barr Virus ( EBV ) and/or Cytomegalovirus ( CMV ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Chronic HCV infection</keyword>
	<keyword>raise ALT</keyword>
	<keyword>transaminitis</keyword>
	<keyword>HCV infection</keyword>
</DOC>